Q3 Revenue Jumps 50% Sequentially as DataMEDS Swings to $10.5M Operating Profit
MEDS is trading near its 52-week low of $0.82 (7.3% above the low).
Summary
DataMEDS reported Q3 2026 revenue up 50% sequentially, driven by its Corexa Pharmacy unit, and swung to a $10.535 million net operating profit from a $34.318 million operating loss a year earlier. Net profit per share was $2.72 on 3.961 million weighted average shares. The profit is largely accounting-driven: the company credits extinguishment of debt and litigation liabilities tied to prior management plus lower management compensation and G&A, not just operating gains. That matters because the last 10-Q (August 17) showed a $26.1M loss, going concern doubt and a Nasdaq equity deficiency — this release says full Nasdaq compliance, including the net equity requirement, was regained October 19. Management also flagged new revenue channels: a non-binding MOU with a Florida HMO covering 25,000+ members (definitive agreements expected in Q4 2026), a November launch of compounded peptides, the REBOOT GLP-1 license, and the Helomics diagnostics lab acquired in September. Watch whether the HMO MOU converts to a definitive agreement in Q4 and whether the profit repeats once one-time debt extinguishment gains drop out.
At the time of this announcement, MEDS was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.82 to $35.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.